Biotech

All Articles

BMS ditches TIGIT, bowing out $200M bet on Agenus bispecific

.Bristol Myers Squibb is actually axing another large bet from the Caforio age, terminating an offer...

Nuvation standstills wager inhibitor after looking at phase 1 data

.After checking out at phase 1 information, Nuvation Bio has actually made a decision to stop work w...

' Medical instinct' led FDA experts to support Zevra's unusual illness med

.Zevra Therapeutics' unusual condition medicine appears to become on the course to approval this fal...

Pfizer takes $230M hit after axing neglected DMD gene treatment

.Pfizer's stage 3 Duchenne muscle dystrophy (DMD) gene treatment failure has gone a $230 thousand op...

AC Immune finds 'landmark' prospective in Alzheimer's medication data

.After much more than twenty years of deal with neurodegenerative health conditions, Swiss biotech a...

GSK goes down ph. 2 HPV injection over shortage of best-in-class prospective

.GSK has scrapped a phase 2 individual papillomavirus (HPV) vaccination from its own pipe after maki...

OS Therapies refiles $6M IPO to fund HER2 medication, preclinical ADCs

.Operating system Therapies are going to specify on the NYSE American supply exchange today using a ...

ALX's fizzling CD47 response fee sends out stock spiraling down

.ALX Oncology's stage 2 stomach cancer feedback cost has actually compromised. After observing its o...

Ionis centers eye condition coming from aim ats of Roche-partnered prospect after records disappoint

.An Additional of Ionis Pharmaceuticals' key midphase readouts has actually fallen short of assumpti...

Biogen's CEO stated no dangerous sell 2023. He's ready to be vibrant

.While Biogen's pharma peers are actually hunting for late-stage assets with little bit of danger, c...